Last reviewed · How we verify
Semaglutide Pill
Semaglutide Pill, marketed by Medanta, The Medicity, India, is a pharmaceutical product with a key composition patent expiring in 2028. Its primary competitive advantage lies in its current market presence, leveraging the established mechanism of semaglutide. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Semaglutide Pill |
|---|---|
| Also known as | Semaglutide 3 mg, Semaglutide 7 mg, Semaglutide 14 mg, Rybelsus |
| Sponsor | Medanta, The Medicity, India |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function (NA)
- Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD) (PHASE2)
- Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus (NA)
- Triple Therapy in T1DM (PHASE2, PHASE3)
- Genetics of the Acute Response to Oral Semaglutide (NA)
- A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range (PHASE1)
- COMMETS- Combination MCI Metabolic Syndrome (PHASE2)
- A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide Pill CI brief — competitive landscape report
- Semaglutide Pill updates RSS · CI watch RSS
- Medanta, The Medicity, India portfolio CI